Castle Biosciences recognized on Newsweek's 2025 America's Greatest Companies list for commitment to innovation and patient care.
Quiver AI Summary
Castle Biosciences, Inc., a diagnostics company focused on innovative healthcare solutions, has been named to Newsweek's inaugural 2025 America’s Greatest Companies list, recognizing 650 U.S. companies for their outstanding performance in financial strength, workforce dedication, innovation, and corporate ethics. CEO Derek Maetzold highlighted the company's mission to prioritize people in all aspects of its work, from developing tests that enhance patient outcomes to fostering a culture of innovation. The evaluation process included assessments of company reviews and data from various third-party sources. Castle Biosciences specializes in tests for conditions such as skin cancers and Barrett’s esophagus, and is actively developing new diagnostic tools to improve treatment options for patients with high clinical needs.
Potential Positives
- Castle Biosciences has been recognized in Newsweek's inaugural 2025 America's Greatest Companies list, highlighting its strong performance in financial strength, workforce dedication, innovation, and commitment to sustainability and ethics.
- This recognition validates Castle Biosciences' commitment to patient care and innovation, enhancing its reputation within the healthcare sector.
- The acknowledgment from a reputable publication like Newsweek can positively impact investor perception and stakeholder confidence in the company's future prospects.
- Inclusion in such an esteemed list may attract potential partnerships and collaborations, opening new avenues for business growth and research development.
Potential Negatives
- The press release highlights Castle Biosciences' inclusion in a prestigious list, but it does not provide any substantial details about the company's financial performance or specific impacts on revenue or growth, which raises questions about the actual significance of the recognition.
- While the company emphasizes its commitment to innovation and patient care, there is no mention of recent innovations or specific examples that showcase how these commitments translate into operational success or market advantage.
- The press release focuses heavily on positive recognitions without addressing any potential challenges or ongoing concerns in the industry, which may lead to perceptions of transparency issues regarding the company's current standing and future prospects.
FAQ
What recognition did Castle Biosciences receive in 2025?
Castle Biosciences was included in Newsweek's inaugural 2025 America’s Greatest Companies list.
What criteria were used to evaluate the companies?
Evaluations were based on financial strength, workforce dedication, innovation, and commitment to sustainability and ethics.
Who is the CEO of Castle Biosciences?
Derek Maetzold is the president and chief executive officer of Castle Biosciences.
What services does Castle Biosciences provide?
Castle Biosciences provides innovative diagnostic tests for conditions like skin cancers and Barrett’s esophagus.
How can I learn more about Castle Biosciences?
You can visit their website at www.CastleBiosciences.com and follow them on social media.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CSTL Insider Trading Activity
$CSTL insiders have traded $CSTL stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 31 sales selling 79,561 shares for an estimated $1,591,590.
- KRISTEN M OELSCHLAGER (Chief Operating Officer) has made 0 purchases and 2 sales selling 30,684 shares for an estimated $669,706.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CSTL Hedge Fund Activity
We have seen 86 institutional investors add shares of $CSTL stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 630,133 shares (+243.9%) to their portfolio in Q2 2025, for an estimated $12,867,315
- PARK WEST ASSET MANAGEMENT LLC removed 556,485 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,363,423
- BRAIDWELL LP added 457,488 shares (+125.3%) to their portfolio in Q2 2025, for an estimated $9,341,904
- WELLINGTON MANAGEMENT GROUP LLP removed 421,317 shares (-50.9%) from their portfolio in Q2 2025, for an estimated $8,603,293
- NUVEEN, LLC added 401,296 shares (+59.7%) to their portfolio in Q2 2025, for an estimated $8,194,464
- PRINCIPAL FINANCIAL GROUP INC added 331,101 shares (+22.6%) to their portfolio in Q2 2025, for an estimated $6,761,082
- UBS GROUP AG added 315,089 shares (+646.2%) to their portfolio in Q2 2025, for an estimated $6,434,117
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CSTL Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/09/2025
- Scotiabank issued a "Sector Outperform" rating on 05/21/2025
- Lake Street issued a "Buy" rating on 05/06/2025
To track analyst ratings and price targets for $CSTL, check out Quiver Quantitative's $CSTL forecast page.
$CSTL Price Targets
Multiple analysts have issued price targets for $CSTL recently. We have seen 3 analysts offer price targets for $CSTL in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $37.0 on 09/09/2025
- Sung Ji Nam from Scotiabank set a target price of $40.0 on 05/21/2025
- Thomas Flaten from Lake Street set a target price of $35.0 on 05/06/2025
Full Release
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics.
“This recognition from Newsweek underscores the power of our commitment to ‘put people first' in everything we do, from pioneering molecular tests that may improve patient outcomes, to building a culture that inspires innovation and excellence,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We’re proud that our dedication to advancing patient care resonates across all facets of our business.”
Evaluations were based on company reviews, filings with the U.S. Securities and Exchange Commission (SEC) and Patent and Trademark Office (USPTO), and third-party data sources to provide an objective measure of corporate performance.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram .
DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
[email protected]
Media Contact:
Allison Marshall
[email protected]
Source: Castle Biosciences Inc.
